Sherzod Abdukadirov

Sherzod Abdukadirov

  • Research Fellow

Sherzod Abdukadirov is a research fellow in the Regulatory Studies Program at the Mercatus Center at George Mason University. He specializes in the federal regulatory process, institutional reforms, food and health, and social complexity.

Abdukadirov has prepared numerous policy briefs on regulatory issues, has written for US News & World Report, and also for scholarly journals such as Regulation, Constitutional Political Economy, and Asian Journal of Political Science.

Abdukadirov received his PhD in public policy from George Mason University and his BS in information technology from Rochester Institute of Technology.

Published Research

Working Papers

Sherzod Abdukadirov, Scott King, David Wille | May 17, 2016
Over the past few years, the federal government and local governments have increasingly turned to “nudges” as solutions to many problems caused by behavioral biases. Such efforts often run into opposition owing to their paternalistic nature, but nonpaternalistic nudges can be equally effective at improving consumers’ choices. In contrast to paternalistic nudges, nonpaternalistic policies do not impose policymakers’ errors on consumers if policymakers misdiagnose the underlying behavioral bias, and they thus avoid harming consumers by pushing them toward suboptimal choices.
Sherzod Abdukadirov | Apr 28, 2015
This paper argues that health advocates are too quick to blame consumers for the ineffectiveness of information disclosure policies. Using the NFP as an example, the paper shows that information disclosures are often poorly designed and fail to actually inform consumers. They often fail to account for how consumers perceive and interpret information or for the differences in their socioeconomic backgrounds. Thus, it may not be consumers’ behavioral biases but rather poor policy design and implementation that is responsible for the NFP’s ineffectiveness. Consequently, the paper argues that nutrition labels should follow smart disclosure principles, which emphasize information salience and usability.
Sherzod Abdukadirov | May 29, 2014
Over the decades, regulatory reforms have sought to increase agency accountability and improve the quality of regulatory analysis and decision-making, with varying success. In this paper, I draw upon previous reform experiences to identify four criteria for effective reforms.
Sherzod Abdukadirov | Dec 18, 2012
This study attempts to shed some light on whether the benefits claimed by the federal agencies are likely to be achieved. In contrast to other validation studies, the study focuses on the agencies’ benefit claims rather than the actually measured benefits. Since agencies justify their regulatory decisions based on expected benefits, examining the quality of these claims is important.


Policy Briefs

Testimony & Comments

Research Summaries & Toolkits

Media Clippings

Expert Commentary

Sep 14, 2016

If we want to avoid similar drug price increases in the future, we need to reduce regulatory barriers in order to encourage innovation and foster greater competition in the pharmaceutical market. Otherwise, we will remain at the mercy of the big pharma companies charging monopolistic prices.
Jul 13, 2016

The conflict between FDA experts and patients underscores the contradictions in the current drug-approval process. In addition, it raises the question of whether the FDA should be in position to prevent well-informed patients from gaining access to drugs.
Jun 06, 2016

Those who adamantly defend the FDA's stringent safety and efficacy requirements overlook the real costs of such policy: Drugs take considerably longer to reach patients, and when they do get to the market, they are often priced beyond the reach of many patients.
May 11, 2016

Exorbitant drug prices are clearly a problem; however, price controls are unlikely to solve it. While price controls may provide immediate financial relief to some patients, they will also reduce future research and development spending and lead to fewer drugs being developed.


Sherzod Abdukadirov | August 29, 2016
Sherzod Abdukadirov talks to host Jim Bohannon about the EpiPen price increase.
' '